ArticleChemical science2026
A biomimetic glycosylated peptide sensor with enhanced assaying accuracy in complex biofluids.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of electrochemical biosensing platforms in complex biological matrices is hindered by the combined effects of biofouling and enzymatic degradation of receptive or supporting interfacial elements. Here, bioinspired by the vascular endothelial glycocalyx, we introduce a β-d-glucose (β-d-Glc) moiety at the C-terminus of sensor-integrated peptide sequences to markedly enhance peptide-water interactions, reduce nonspecific adsorption, and protect the peptide backbone from proteolytic cleavage. Integrated experimental and all-atom molecular dynamic (MD) numerical investigations demonstrate that incubations in clinical human serum are associated with much higher levels of resistance. Interfacial aptamer co-immobilization then supports highly effective specific target recognition. The so-generated glycosylated peptide (GP) sensors display high detection accuracy (compared to hospital standards) and promising clinical applicability, over and above that possible with analogous non-glycosylated peptide (non-GP) analogues. This work, then, establishes a new, versatile and highly-accessible strategy to support highly challenging and diagnostically-impactful molecular detection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.